Prostate cancer recurrence after surgery is nearly double in smokers
the ONA take:
New research points out another cancer prognosis worsened by smoking. This research from an international group of scientists and clinicians from the United States and Europe found that current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
The group retrospectively reviewed biochemical prostate cancer recurrence in 7,191 men who had undergone radical prostatectomy.
Among the men, approximately one-third each were never smokers, former smokers, and current smokers. After a median follow-up of 28 months, current smokers had approximately double the chance of the cancer recurring. Those who had quit within the last 10 years had a significantly higher risk.
The researchers report that their results confirm what is seen in many other cancers: smoking increases the risk of recurrence after initial treatment.
Furthermore, they recommend that patients stop smoking after a diagnosis of prostate cancer is determined.
Current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- G-CSF May Help Preserve Fertility in Male Patients With Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade
- Scalp Cooling Reduces Risk of Chemotherapy-Induced Alopecia
- CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|